AR and COVID-19: Although the HITCH trial reported that androgen suppression through Degarelix treatment did not improve outcomes in a small cohort of men hospitalized with COVID-19, other trials found proxalutamide, an androgen receptor antagonist, was an effective treatment for non-hospitalized patients with COVID-19 (Cadegiani et al., 2021; McCoy et al., 2021; Nickols et al., 2022).